Isabelle Huys

8.1k total citations
223 papers, 4.5k citations indexed

About

Isabelle Huys is a scholar working on Economics and Econometrics, Immunology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Isabelle Huys has authored 223 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Economics and Econometrics, 55 papers in Immunology and 42 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Isabelle Huys's work include Health Systems, Economic Evaluations, Quality of Life (92 papers), Pharmaceutical Economics and Policy (78 papers) and Biosimilars and Bioanalytical Methods (52 papers). Isabelle Huys is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (92 papers), Pharmaceutical Economics and Policy (78 papers) and Biosimilars and Bioanalytical Methods (52 papers). Isabelle Huys collaborates with scholars based in Belgium, Netherlands and United States. Isabelle Huys's co-authors include Steven Simoens, Arnold G. Vulto, Minne Casteels, Gilbert Verbeken, Daniël De Vos, Eline van Overbeeke, Jean‐Paul Pirnay, Kim Pauwels, Paul Declerck and Liese Barbier and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Nature Biotechnology.

In The Last Decade

Isabelle Huys

208 papers receiving 4.3k citations

Peers

Isabelle Huys
Dean A. Regier Canada
Peter B. Gilbert United States
Jamie Lopez Bernal United Kingdom
Yonatan H. Grad United States
James Wagner United States
Dermot Maher Switzerland
Siddappa N. Byrareddy United States
John Abraham United States
Michael G. Hudgens United States
Dean A. Regier Canada
Isabelle Huys
Citations per year, relative to Isabelle Huys Isabelle Huys (= 1×) peers Dean A. Regier

Countries citing papers authored by Isabelle Huys

Since Specialization
Citations

This map shows the geographic impact of Isabelle Huys's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Huys with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Huys more than expected).

Fields of papers citing papers by Isabelle Huys

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Huys. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Huys. The network helps show where Isabelle Huys may publish in the future.

Co-authorship network of co-authors of Isabelle Huys

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Huys. A scholar is included among the top collaborators of Isabelle Huys based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Huys. Isabelle Huys is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morgan, Kate, Ariel Aviv, Varda Shoham, et al.. (2025). Patients and healthcare professionals’ perspectives on the implementation of shared decision making in multiple myeloma: a multinational qualitative study. BMC Medical Informatics and Decision Making. 25(1). 432–432.
2.
Outtier, An, Rosanne Janssens, Liese Barbier, et al.. (2024). Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis. United European Gastroenterology Journal. 13(4). 542–551. 2 indexed citations
3.
Barbier, Liese, Walter Droogné, Peter Sinnaeve, et al.. (2024). Heart Failure Patients' Perspectives on Treatment Outcomes and Unmet Medical Needs: A Qualitative Preference Study. ESC Heart Failure. 11(5). 3075–3084. 1 indexed citations
4.
Valcke, Peggy, et al.. (2024). EU-US data transfers: an enduring challenge for health research collaborations. npj Digital Medicine. 7(1). 215–215. 5 indexed citations
5.
Borry, Pascal, et al.. (2023). Informing a European guidance framework on electronic informed consent in clinical research: a qualitative study. BMC Health Services Research. 23(1). 181–181. 5 indexed citations
6.
Vulto, Arnold G., et al.. (2022). Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe. BioDrugs. 36(2). 217–229. 17 indexed citations
7.
8.
Overbeeke, Eline van, Mondher Toumi, Hilde Stevens, et al.. (2020). Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discovery Today. 26(2). 399–415. 29 indexed citations
9.
Zaçe, Drieda, Stefania Boccia, María Luisa Di Pietro, et al.. (2020). Implementation of Electronic Informed Consent in Biomedical Research and Stakeholders’ Perspectives: Systematic Review. Journal of Medical Internet Research. 22(10). e19129–e19129. 52 indexed citations
10.
Moorkens, Evelien, Arnold G. Vulto, & Isabelle Huys. (2020). Biosimilars in Belgium: a proposal for a more competitive market. Acta Clinica Belgica. 76(6). 441–452. 16 indexed citations
11.
Hoxhaj, Ilda, Steven Simoens, Walter Van Dyck, et al.. (2020). A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies. International Journal of Environmental Research and Public Health. 17(21). 8001–8001. 7 indexed citations
12.
Moorkens, Evelien, Arnold G. Vulto, Martin Schulz, et al.. (2020). Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. Pharmaceuticals. 13(10). 324–324. 22 indexed citations
13.
Moorkens, Evelien, et al.. (2020). Economic evaluation of biosimilars for reimbursement purposes – what, when, how?. SHILAP Revista de lepidopterología. 8(1). 1739509–1739509. 9 indexed citations
14.
Moorkens, Evelien, Arnold G. Vulto, & Isabelle Huys. (2020). An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?. mAbs. 12(1). 1743517–1743517. 32 indexed citations
15.
16.
Overbeeke, Eline van, et al.. (2019). Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium. Orphanet Journal of Rare Diseases. 14(1). 99–99. 85 indexed citations
17.
Stevens, Hilde, Geertrui Van Overwalle, Bart Van Looy, & Isabelle Huys. (2015). Innovative Medicines Initiative (IMI) Case Study Analysis Reveals the True Added Value of Early-Phase Public-Private Partnerships (PPPs). Biotechnology Law Report. 34(4). 153–165. 4 indexed citations
18.
Verbeken, Gilbert, Isabelle Huys, Jean‐Paul Pirnay, et al.. (2014). Taking Bacteriophage Therapy Seriously: A Moral Argument. BioMed Research International. 2014. 1–8. 32 indexed citations
19.
Stevens, Hilde, Geertrui Van Overwalle, Bart Van Looy, & Isabelle Huys. (2013). Perspectives and Opportunities for Precompetitive Public–Private Partnerships in the Biomedical Sector. Biotechnology Law Report. 32(3). 131–139. 21 indexed citations
20.
Nirthanan, Selvanayagam, Isabelle Huys, Toshiyuki Kohno, et al.. (2004). Synthesis and Characterization of Spinoxin, a Novel Peptide Toxin from the Malaysian Black Scorpion. 2003. 283–284. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dean A. Regier Breakdown of academic impact, for papers by Peter B. Gilbert Breakdown of academic impact, for papers by Jamie Lopez Bernal Breakdown of academic impact, for papers by Yonatan H. Grad Breakdown of academic impact, for papers by James Wagner Breakdown of academic impact, for papers by Dermot Maher Breakdown of academic impact, for papers by Siddappa N. Byrareddy Breakdown of academic impact, for papers by John Abraham Breakdown of academic impact, for papers by Michael G. Hudgens
Rankless by CCL
2026